Canadian Antimicrobial
Innovation Coalition

According to the World Health Organization (WHO), antimicrobial resistance (AMR) refers to a resistance to drugs that help treat infections caused by microbes such as parasites, viruses, and fungi.

read more

Canadian Antimicrobial
Innovation Coalition

The Canadian Antimicrobial Innovation Coalition (CAIC) is a coalition Canada’s key players in the biomedical innovation industry and research-based organizations in collaboration with these industries. CAIC aims to engage the public, health sector and government in strategies to help protect Canadians from the dangerous rise in antimicrobial resistance (AMR).

What we do

CAIC’s mandate is to protect the Canadian population from the rise in antimicrobial resistance, by positioning Canada to be a leader in AMR research and product development, economic growth, and investment.

CAIC aims to facilitate necessary dialogue and collaboration between relevant partners such as regulators, public policymakers, researchers, and manufacturers. Through its influential membership, CAIC seeks to advocate for certain policy initiatives and advise government officials on appropriate research mechanisms, regulatory incentives aimed at strengthening efforts to combat AMR in Canada, and methods to overcome market barriers.

CAIC will also contribute to the Pan-Canadian Framework for Action for Tackling Antimicrobial Resistance and Antimicrobial Use, with specific focus on the Research and Innovation pillar in an advisory capacity.

Our members

Biopharmaceutical

Diagnostic

Research

Become a Member